Vision-Restoring Chip Receives European Union Approval

A startup company, Science Corporation, has achieved a significant milestone by securing European Union approval to sell a device designed to restore vision for individuals suffering from age-related macular degeneration (AMD). This condition affects millions worldwide, damaging light-sensitive cells in the retina and impairing the ability to read and recognize faces.

The device, named PRIMA, aims to combat vision loss caused by AMD. It targets the specific cells at the back of the eye that are degraded by the disease. This breakthrough offers hope to those affected by a condition that severely impacts daily life and independence.

While the initial price of the PRIMA device is considerable, the company anticipates that mass production could lead to a substantial reduction in costs. This potential for affordability in the future makes the technology more accessible to a wider patient population. The European regulatory approval marks a crucial step towards making this vision-restoring technology available on the market.